Computational Drug Discovery
Structure-based drug design, molecular modelling and computational chemistry for early discovery and lead-development questions.
MOLECIVA is a scientific consultancy combining computational chemistry, molecular modelling, drug discovery and advanced protein design to turn complex biological questions into actionable research strategies.
We combine structure, computation and scientific reasoning to investigate molecular systems and identify practical next steps for research programmes.
Structure-based drug design, molecular modelling and computational chemistry for early discovery and lead-development questions.
De novo protein and minimal-enzyme design using modern generative and structure-guided approaches.
Molecular dynamics and free-energy methods are being developed as additional capabilities for deeper mechanistic and energetic analysis.
Services are designed around defined scientific problems rather than generic computational packages.
Molecular modelling, structure-based drug design and computational analysis.
Application of modern machine-learning approaches to molecular discovery problems.
De novo protein design and structure-guided protein engineering strategies.
Computational exploration of compact enzyme scaffolds and catalytic architectures.
Structural analysis of molecular recognition and protein–ligand interactions.
Professional editing of scientific manuscripts for clarity, structure and technical communication.
Scientific problem definition, computational strategy and interpretation of molecular data.
Focused computational training for researchers and scientific teams.
Each project begins with the biological question and ends with an evidence-based interpretation of what the computation can—and cannot—support.
Clarify the biological question.
Analyse structures and evidence.
Apply appropriate methods.
Test computational evidence.
Support the next research decision.
MOLECIVA is a Mumbai-based scientific consultancy serving research teams globally. The company works at the intersection of molecular science, computational drug discovery and advanced protein design.
It is founded by Elvis A. F. Martis, PhD.
Tell us about the scientific question, desired outcome and research context.
MOLECIVA is a scientific consultancy combining computational chemistry, molecular modelling, drug discovery and advanced protein design to turn complex biological questions into actionable research strategies.
We combine structure, computation and scientific reasoning to investigate molecular systems and identify practical next steps for research programmes.
Structure-based drug design, molecular modelling and computational chemistry for early discovery and lead-development questions.
De novo protein and minimal-enzyme design using modern generative and structure-guided approaches.
Molecular dynamics and free-energy methods are being developed as additional capabilities for deeper mechanistic and energetic analysis.
Services are designed around defined scientific problems rather than generic computational packages.
Molecular modelling, structure-based drug design and computational analysis.
Application of modern machine-learning approaches to molecular discovery problems.
De novo protein design and structure-guided protein engineering strategies.
Computational exploration of compact enzyme scaffolds and catalytic architectures.
Structural analysis of molecular recognition and protein–ligand interactions.
Professional editing of scientific manuscripts for clarity, structure and technical communication.
Scientific problem definition, computational strategy and interpretation of molecular data.
Focused computational training for researchers and scientific teams.
Each project begins with the biological question and ends with an evidence-based interpretation of what the computation can—and cannot—support.
Clarify the biological question.
Analyse structures and evidence.
Apply appropriate methods.
Test computational evidence.
Support the next research decision.
MOLECIVA is a Mumbai-based scientific consultancy serving research teams globally. The company works at the intersection of molecular science, computational drug discovery and advanced protein design.
It is founded by Elvis A. F. Martis, PhD.
Tell us about the scientific question, desired outcome and research context.